Where does Nikang Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Nikang Therapeutics, Inc. ranks #20,153 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Nikang Therapeutics, Inc. hold?

Nikang Therapeutics, Inc. holds 14 US utility patents granted between 2021 and 2025, spanning 5 technology areas.

What is Nikang Therapeutics, Inc.'s Innovation Score?

Nikang Therapeutics, Inc. has an Innovation Score of 51.7 out of 100 (top 11% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Nikang Therapeutics, Inc. focus on?

Nikang Therapeutics, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 12 patents, ranking #1,593 of 6,058 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Nikang Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Nikang Therapeutics, Inc..

What does claim depth mean for Nikang Therapeutics, Inc.'s patents?

Nikang Therapeutics, Inc.'s patents average 24.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Nikang Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Nikang Therapeutics, Inc.

USPTO PatentsView assignee record - 14 granted patents across 5 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Nikang ranks #20,153 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 5 technology areas.

#20,153
of 49,997 US assignees by volume: Top 11%
by Innovation Score (51.7/100): 24.1
avg claims per patent

USPTO PatentsView assignee plate

Corpus R20153 · US Corporation #20,153 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 14 grants
MID-PACK #20,153/49,997
PHOTO-FINISH Nichirei Foods
CPC-NARROW A61P · 5 areas
INNOV-PAR 51.7/100
CLAIMS-DENSE 24.1 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2021–2025 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Nichirei Foods Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Nikang’s 51.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.4 pts (18%) Velocity 20.0 pts (39%) Breadth 7.9 pts (15%) Claim depth 14.4 pts (28%)

Qualcomm Incorporated · highest

85
Nikang Therapeutics · this assignee

52
3D Lighting… · lowest

7

What this shows Nikang's Innovation Score is 51.7/100 (top 11% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Nikang?

Each dot is one of Nikang’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Nikang’s own 24.1 claims/patent is ABOVE the 10.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Nikang vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Nikang's grants concentrate

Nikang Therapeutics, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 85.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2022 (4 grants) versus a trough of 2 in 2021. By volume, Nikang sits between Nichirei Foods Inc. and NO Sacrifice Bags Inc..

Nikang's three-year grant acceleration

Nikang Therapeutics, Inc. shows 8 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Nichirei Foods

14
Nicox

14
Nidec Control Tec…

14
Nidec Global Appl…

14
Ninebot (Changzho…

14
Ninepoint Medical

14
Ningbo Lisi House…

14
NO Sacrifice Bags

14
Nikang Therapeuti… ◀

14

What this shows Nikang holds 14 patents at rank #20,136, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Nikang

By rank, the assignees closest to #20,136 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Nikang's primary technology class.

Nikang's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

52 Top 11% higher than 89% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Nikang Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	2	14.3%
2022	4	28.6%
2023	2	14.3%
2024	2	14.3%
2025partial year	4	28.6%

Which technologies does Nikang Therapeutics, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 12

C07D - Heterocyclic Compounds 11

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 11

C07C - Acyclic OR Carbocyclic Compounds 7

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 6

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Nikang Therapeutics, Inc.'s patent record in context - here's where to go next.

Nikang Therapeutics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 85.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #20,153 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Nikang Therapeutics, Inc. against Nichirei Foods Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 51.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.